
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is benefiting from its expansion into full-risk contracts and its conservative approach to reserving and managing patient utilization, resulting in strong cash flow and positive margins. The company is on track to surpass its synergy targets and remains well-positioned for future growth in its Medicare and Medicaid markets. Its strong Q1 performance and favorable outlook for 2027 contribute to a positive outlook for the company's stock.
Bears say
Astrana Health is currently going through a period of transition and integration, which may cause disruption and result in underperformance. Additionally, the company is facing execution risks associated with its recent acquisition of Prospect Health, as it works to align operations, risk contract performance, and provider networks. The company also faces potential challenges related to its high valuation and potential volatility in the healthcare industry, including increased utilization levels and delays in realizing savings from care-management initiatives. These factors may negatively impact the company's financial results, creating downside risk to its earnings and cash flow in the near term.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares